Research on artificial disc replacement following anterior decompression tops January’s Top 10 Spinal News International articles. Also popular this month were findings on the link between adult spinal deformity and work and school absenteeism, as well as news on a number of regulatory clearances for a range of devices.
There is no clear benefit associated with artificial disc replacement (ADR) compared with fusion surgery when it comes to patient satisfaction, sustainability, and protection against adjacent-segment pathology (ASP) in those who have received anterior decompression due to cervical degenerative radiculopathy. This is main finding of new research which was published in the Journal of Neurosurgery: Spine by Michael Kontakis (Uppsala University Hospital, Uppsala, Sweden) et al.
Surgalign Holdings has announced that it has received US Food and Drug Administration (FDA) 510(k) clearance for its HOLO Portal surgical guidance system for use within lumbar spine procedures.
SynerFuse has announced the first implantation in the company’s proof-of-concept study, which will evaluate the safety and tolerability of simultaneously implanting spinal fusion hardware and a dorsal root ganglion (DRG) neurostimulator in patients suffering from chronic lower back pain.
The use of a standalone expandable cage in the cervical spine after one or two-level anterior cervical corpectomy and fusion (ACCF) without additional posterior fixation or anterior plating is a safe procedure that results in fusion, new research has shown.
Adult spinal deformity (ASD) surgery is associated with increased productivity and decreased absenteeism from both work and school. These are the key findings from a recent retrospective cohort study, the findings of which were published by Wesley Durand (Johns Hopkins University, Baltimore, USA) et al in the journal Spine.
Abbott has announced that the US Food and Drug Administration (FDA) has approved new expanded magnetic resonance imaging (MRI) compatibility for its Proclaim XR spinal cord stimulation (SCS) system with Octrode leads.
The use of once-daily risdiplamin in type 2 and non-ambulant type 3 spinal muscular atrophy (SMA) patients leads to a significant improvement in motor function when compared to placebo. This is according to the latest data from the SUNFISH clinical trial, the findings of which were published by Eugenio Mercuri (Catholic University, Rome, Italy) et al in The Lancet: Neurology.
Inspan LLC has announced that it has received US Food and Drug Administration (FDA) clearance for its interspinous plate fixation device to be used for spinal fusion and spinal stenosis from T1-S1.
Medtronic has received US Food and Drug Administration (FDA) approval of its Intellis rechargeable neurostimulator and Vanta recharge-free neurostimulator for the treatment of chronic pain associated with diabetic peripheral neuropathy (DPN).
NuVasive has announced that it has received US Food and Drug Administration (FDA) 510(k) clearance for expanded indications of use for Attrax Putty with its thoracolumbar interbody portfolio for spine surgery.